The Trump administration’s new executive order aims to accelerate FDA review of psychedelic therapies for mental health conditions, highlighting a potential shift in regulatory timelines and expanded access pathways,
The Trump administration issued a new executive order aiming to accelerate research and regulatory review of psychedelic therapies for mental health conditions.
Emerging Pharma Leaders nominations are now open!
Do you know someone who can make tough decisions that continue to face manufacturers? Are they destined to change the future of pharma?
Nominate a colleague with impressive leadership and career intentions – even yourself! – for the Pharmaceutical Executive 2026 Emerging Pharma Leaders Awards.
The decision signals a potential shift in how emerging treatments for disorders such as post-traumatic stress disorder (PTSD), anxiety, and depression are evaluated in the United States.
“We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have,” said Kabir Nath, CEO at Compass Pathways.3
Signed in the Oval Office over the weekend, the order directs the FDA to expedite its review of certain investigational therapies, particularly those already in advanced stages of clinical development, with an initial focus on addressing unmet needs among U.S. veterans.1
President Trump framed the move as part of a broader effort to expand access to novel treatment options for patients with limited alternatives.
“Today’s order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life,” Trump said.
The policy highlights psychedelic compounds as an area of interest, including ibogaine, which has been studied internationally for its potential role in treating PTSD and substance use disorders.1
Along with signing the order, the administration also indicated it’s plans to explore pathways for incorporating such treatments under the Right to Try Act, which enables eligible patients with life-threatening conditions to access investigational therapies outside of clinical trials.1
FDA Commissioner Martin Makary suggested the initiative could significantly compress regulatory timelines for qualifying therapies. “Under this new program in this administration, drugs can get approved in weeks, not a year or year plus, but in weeks, if they are in line with our national priorities,” he said, noting that the agency is expanding a voucher-based program intended to accelerate reviews for treatments targeting urgent public health needs.2
The announcement reflects growing interest in psychedelic-based therapeutics across the biopharmaceutical sector, where several companies are advancing clinical programs targeting mental health disorders that have historically been difficult to treat.
While early-stage and mid-stage data have shown promise, regulatory pathways remain uncertain, and questions around long-term safety, durability of effect, and appropriate clinical frameworks continue to shape the field.
Another factor influencing the administration’s decision to sign the order is the involvement of public figures, specifically podcaster Joe Rogan, who says he shared information about the therapies directly with the president, following a podcast with HHS secretary Robert F. Kennedy Jr.
“I sent him that information. The text message that came back: ‘Sounds great. Do you want FDA approval? Let’s do it.’ Literally that quick,” said Rogan, who joined President Trump in the Oval Office during the executive order’s signing.2
The action underscores the increasing visibility of psychedelic research beyond traditional scientific and medical channels. However, it also raises questions about how emerging evidence is translated into policy decisions, particularly in a highly regulated area such as drug approval.
From a policy perspective, the executive order introduces both opportunity and complexity, as accelerated timelines hold the potential to help bring innovative therapies to patients at an increased rate, particularly in areas of high unmet need such as veteran mental health.
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
